Business Organization and Liquidity	6 Months Ended
Jun. 30, 2026
Accounting Policies [Abstract]
Business Organization and Liquidity	1. Business Organization and Liquidity Scribe Therapeutics Inc. (the “Company”) is a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention. The Company was incorporated in the state of Delaware in June 2017. Its principal offices are in Alameda, California. Liquidity and Going Concern The accompanying unaudited condensed financial statements have been prepared under the assumption that the Company will continue as a going concern. Since inception, the Company has devoted substantially all of its efforts to research and development activities, establishing and protecting its intellectual property, recruiting personnel, raising capital and conducting business planning. The Company has funded its operations primarily through proceeds received from collaboration and license agreements and the issuance of redeemable convertible preferred stock. As of June 30, 2026, the Company had cash, cash equivalents and available-for-sale investments of $43.0 million. The Company has incurred recurring losses and negative cash flows from operations since inception. Net losses were $23.8 million and $13.3 million for the six months ended June 30, 2026 and 2025, respectively. As of June 30, 2026, the Company had an accumulated deficit of $181.5 million. On July 27, 2026, the Company completed its initial public offering ("IPO") of 9,867,000 shares of common stock, which included the full exercise by the underwriters of their option to purchase an additional 1,287,000 shares, at a public offering price of $15.00 per share. Gross proceeds from the IPO were approximately $148.0 million, before underwriting discounts, commissions and offering expenses. Concurrently with the IPO, the Company completed a private placement of 500,000 shares of common stock to an affiliate of Sanofi at a price of $15.00 per share, resulting in gross proceeds of $7.5 million. In aggregate, the IPO and concurrent private placement generated approximately $155.5 million of gross proceeds. After deducting underwriting discounts, commissions and other offering costs, the Company received net proceeds of approximately $140.7 million from the IPO and concurrent private placement. The Company believes that its existing cash, cash equivalents and available-for-sale investments, together with the net proceeds from the IPO and the concurrent private placement, will be sufficient to fund its planned operating expenses and capital expenditure requirements for at least the next twelve months from the issuance date of these financial statements. Accordingly, management concluded that the substantial doubt about the Company's ability to continue as a going concern that existed as of June 30, 2026 was alleviated prior to the issuance of these financial statements as a result of the completion of the IPO and concurrent private placement.

Business Organization and Liquidity

6 Months Ended

Jun. 30, 2026

1. Business Organization and Liquidity

Scribe Therapeutics Inc. (the “Company”) is a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention. The Company was incorporated in the state of Delaware in June 2017. Its principal offices are in Alameda, California.

Liquidity and Going Concern

The accompanying unaudited condensed financial statements have been prepared under the assumption that the Company will continue as a going concern.

Since inception, the Company has devoted substantially all of its efforts to research and development activities, establishing and protecting its intellectual property, recruiting personnel, raising capital and conducting business planning. The Company has funded its operations primarily through proceeds received from collaboration and license agreements and the issuance of redeemable convertible preferred stock.

As of June 30, 2026, the Company had cash, cash equivalents and available-for-sale investments of $43.0 million. The Company has incurred recurring losses and negative cash flows from operations since inception. Net losses were $23.8 million and $13.3 million for the six months ended June 30, 2026 and 2025, respectively. As of June 30, 2026, the Company had an accumulated deficit of $181.5 million.

On July 27, 2026, the Company completed its initial public offering ("IPO") of 9,867,000 shares of common stock, which included the full exercise by the underwriters of their option to purchase an additional 1,287,000 shares, at a public offering price of $15.00 per share. Gross proceeds from the IPO were approximately $148.0 million, before underwriting discounts, commissions and offering expenses. Concurrently with the IPO, the Company completed a private placement of 500,000 shares of common stock to an affiliate of Sanofi at a price of $15.00 per share, resulting in gross proceeds of $7.5 million. In aggregate, the IPO and concurrent private placement generated approximately $155.5 million of gross proceeds.

After deducting underwriting discounts, commissions and other offering costs, the Company received net proceeds of approximately $140.7 million from the IPO and concurrent private placement. The Company believes that its existing cash, cash equivalents and available-for-sale investments, together with the net proceeds from the IPO and the concurrent private placement, will be sufficient to fund its planned operating expenses and capital expenditure requirements for at least the next twelve months from the issuance date of these financial statements.

Accordingly, management concluded that the substantial doubt about the Company's ability to continue as a going concern that existed as of June 30, 2026 was alleviated prior to the issuance of these financial statements as a result of the completion of the IPO and concurrent private placement.